Heparin inhibits the interaction of DNA topoisomerase I/anti-topoisomerase i immune complexes with heparan sulfate on dermal fibroblasts

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1632-1641

  Arcand, Julie ^a   Robitaille, Geneviève ^a   Koenig, Martial ^a   Senécal, Jean Luc ^a   Raymond, Yves ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; DNA TOPOISOMERASE; ENOXAPARIN; ENZYME ANTIBODY; FONDAPARINUX; HEPARAN SULFATE; HEPARIN; IMMUNOGLOBULIN G; TOPOISOMERASE I AUTOANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DISSOCIATION; ENZYME BINDING; FIBROSIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PATHOGENESIS; PRIORITY JOURNAL; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS;

ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, SURFACE; AUTOANTIBODIES; CELLS, CULTURED; DERMIS; DNA TOPOISOMERASES, TYPE I; FIBRINOLYTIC AGENTS; FIBROBLASTS; HEPARIN; HEPARITIN SULFATE; HUMANS; PROTEIN BINDING; SCLERODERMA, SYSTEMIC;

EID: 84860424367     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33484     Document Type: Article

References (34)

1. Cano PO, Jerry LM, Sladowski JP, Osterland CK,. Circulating immune complexes in systemic lupus erythematosus. Clin Exp Immunol 1977; 29: 197-204.
2. Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 2008; 10: R94.
3. Putterman C,. New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. Autoimmun Rev 2004; 3: 7-11.
4. Naparstek Y, Ben-Yehuda A, Madaio MP, Bar-Tana R, Schuger L, Pizov G, et al. Binding of anti-DNA antibodies and inhibition of glomerulonephritis in MRL-lpr/lpr mice by heparin. Arthritis Rheum 1990; 33: 1554-9.
5. Van Bruggen MC, Walgreen B, Rijke TP, Corsius MJ, Assmann KJ, Smeenk RJ, et al. Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int 1996; 50: 1555-64.
6. Hedberg A, Fismen S, Fenton KA, Fenton C, Osterud B, Mortensen ES, et al. Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes. Arthritis Rheum 2011; 63: 1065-75.
7. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 154-67.
8. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A,. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42: 534-40.
9. Hu PQ, Fertig N, Medsger TA Jr, Wright TM,. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003; 48: 1363-73.
10. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T,. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43: 1074-84.
11. Henault J, Tremblay M, Clement I, Raymond Y, Senecal JL,. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004; 50: 3265-74.
12. Henault J, Robitaille G, Senecal JL, Raymond Y,. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006; 54: 963-73.
13. Senecal JL, Henault J, Raymond Y,. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol 2005; 32: 1643-9.
14. Robitaille G, Christin MS, Clement I, Senecal JL, Raymond Y,. Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells. Arthritis Rheum 2009; 60: 2805-16.
15. Nihtyanova SI, Denton CP,. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6: 112-6.
16. Fineschi S, Goffin L, Rezzonico R, Cozzi F, Dayer JM, Meroni PL, et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of Toll-like receptor 4. Arthritis Rheum 2008; 58: 3913-23.
17. Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002; 46: 1602-13.
18. Ronda N, Gatti R, Giacosa R, Raschi E, Testoni C, Meroni PL, et al. Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. Arthritis Rheum 2002; 46: 1595-601.
19. Jacob L, Viard JP, Allenet B, Anin MF, Slama FB, Vandekerckhove J, et al. A monoclonal anti-double-stranded DNA autoantibody binds to a 94-kDa cell-surface protein on various cell types via nucleosomes or a DNA-histone complex. Proc Natl Acad Sci U S A 1989; 86: 4669-73.
20. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM,. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64: 841-8.
21. Gallagher JT,. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001; 108: 357-61.
22. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-77.
23. Kreuger J, Spillmann D, Li JP, Lindahl U,. Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 2006; 174: 323-7.
24. Parish CR,. Heparan sulfate and inflammation. Nat Immunol 2005; 6: 861-2.
25. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
26. Zeileis A,. Object-oriented computation of sandwich estimators. J Stat Software 2006; 16: 1-16.
27. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. Vienna; 2010.
28. Kovalszky I, Dudas J, Olah-Nagy J, Pogany G, Tovary J, Timar J, et al. Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Mol Cell Biochem 1998; 183: 11-23.
29. Ishii K, Katase A, Andoh T, Seno N,. Inhibition of topoisomerase I by heparin. Biochem Biophys Res Commun 1982; 104: 541-7.
30. Fannon M, Nugent MA,. Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J Biol Chem 1996; 271: 17949-56.
31. Diot E, Giraudeau B, Diot P, Degenne D, Ritz L, Guilmot JL, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999; 116: 715-20.
32. Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease: a prospective study. Arthritis Rheum 1991; 34: 68-77.
33. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M,. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010; 6: 280-9.
34. Arcand J, Robitaille G, Koenig M, Senecal JL, Raymond Y,. The autoantigen DNA topoisomerase I interacts with chemokine receptor 7 and exerts cytokine-like effects on dermal fibroblasts. Arthritis Rheum 2012; 64: 826-34.